Dr. Lammers has disclosed that he has received funding support from NIH K12CA90625. Dr. Lovly has disclosed that she has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Horn has disclosed that she is a PI for a clinical trial funded by Astellas US LLC, she is on the advisory board for Clovis Oncology, and is a speaker for Boehringer Ingelheim GmbH.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Manager, CE Supporter Outreach
Ms. Moonan has disclosed the following relationship with commercial interests: AstraZeneca: Stockholder/Former Employee.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
Pao W, Miller VA, Politi KA et al.. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
Kobayashi S, Boggon TJ, Dayaram T et al.. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–792.
Su Z, Dias-Santagata D, Duke M et al.. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 2011;13:74–84.
Sequist LV, Waltman BA, Dias-Santagata D et al.. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
Ettinger DS, Wood DE, Akerley W et al.. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2, 2014. Available at: NCCN.org. Accessed December 3, 2013.
NCCN Biomarkers Compendium. National Comprehensive Cancer Network Web site. Available at: NCCN.org. Accessed December 3, 2013.
Bergethon K, Shaw AT, Ou SH et al.. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863–870.
Bos M, Gardizi M, Schildhaus HU et al.. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 2013;81:142–143.
Planchard D, Mazieres J, Riely GJ et al.. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 8009.
Gautschi O, Pauli C, Strobel K et al.. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012;7:e23–24.
De Greve J, Teugels E, Geers C et al.. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012;76:123–127.
Drilon A, Wang L, Hasanovic A et al.. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630–635.
Lipson D, Capelletti M, Yelensky R et al.. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382–384.
Mack PC, Holland WS, Burich RA et al.. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 2009;4:1466–1472.
Rosell R, Molina MA, Costa C et al.. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160–1168.
Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res 2012;22:2101–2108.
Sun Y, Ren Y, Fang Z et al.. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010;28:4616–4620.
Ludovini V, Bianconi F, Pistola L et al.. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011;6:707–715.
- Search Google Scholar
- Export Citation
. Ludovini V Bianconi F Pistola L Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; 6: 707– 715.
Chaft JE, Arcila ME, Paik PK et al.. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2012;11:485–491.
Janjigian YY, Smit EF, Horn L et al.. Activity of afatinib/cetuximab in patients with EGFR mutant non-small cell lung cancer and acquired resistance to EGFR inhibitors. Presented at the 37th ESMO Congress; September 28-October 2, 2012; Vienna, Austria.
Bell DW, Gore I, Okimoto RA et al.. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315–1316.
Girard N, Lou E, Azzoli CG et al.. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res 2010;16:755–763.
Tibaldi C, Giovannetti E, Vasile E et al.. Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J Thorac Oncol 2011;6:395–396.